/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Takeda Pharmaceutical Company Limited Share Price Today: Live Updates & Key Insights

Takeda Pharmaceutical Company Limited share price today is $17.83, up -1.55%. The stock opened at $18.12 against the previous close of $18.11, with an intraday high of $18.12 and low of $17.785.

Takeda Pharmaceutical Company Limited Share Price Chart

style
pb-0

Takeda Pharmaceutical Company Limited

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Takeda Pharmaceutical Company Limited Share Price Performance

$17.83 -0.0155(-1.55%) TAK at 23 Mar 2026 03:25 PM Drug Manufacturers - Specialty & Generic
Lowest Today 17.785
Highest Today 18.12
Today’s Open 18.12
Prev. Close 18.11
52 Week High 18.82
52 Week Low 12.99
Day’s Range: Low 17.785 High 18.12
52-Week Range: Low 12.99 High 18.82
1 day return -
1 Week return -2.19
1 month return -5.21
3 month return +18.05
6 month return +18.6
1 year return +18.64
3 year return +8.46
5 year return -10.45
10 year return -

Takeda Pharmaceutical Company Limited Institutional Holdings

Capital Research Global Investors 0.43

American Funds American Mutual A 0.41

Capital Group American Mutual Comp 0.41

Morgan Stanley - Brokerage Accounts 0.24

UBS Group AG 0.19

Arrowstreet Capital Limited Partnership 0.18

The Goldman Sachs Group Inc 0.16

D. E. Shaw & Co LP 0.14

FMR Inc 0.13

Brandes Investment Partners & Co 0.12

BlackRock Inc 0.10

The Toronto-Dominion Bank 0.10

Renaissance Technologies Corp 0.08

First Trust Advisors L.P. 0.08

Van Eck Associates Corporation 0.07

VanEck Pharmaceutical ETF 0.06

First Trust Value Line® Dividend ETF 0.06

Northern Trust Corp 0.06

Managed Asset Portfolios, LLC 0.05

Wells Fargo & Co 0.03

Quantinno Capital Management LP 0.03

VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.03

Millennium Management LLC 0.03

Amplify CWP International Enh Div IncETF 0.03

QRG Capital Management, Inc. 0.03

MAP Global Equity Composite 0.02

Steward Values Enhanced International I 0.02

Capital Group American Mutual Trust U0 0.02

Avantis International Equity ETF 0.01

MAP Global Balanced Composite 0.01

Dimensional All Country ex US LgCap Core 0.01

MAP Global Equity Ex-Options Composite 0.01

MGI Global Equity M-7 € Acc 0.01

Arrowstreet Intl Eq EAFE CL M 0.01

Russell Personalized Core Equity SMA 0.01

Catalyst/MAP Global Equity A 0.01

Mercer Non-US Core Equity Y3 0.01

ActivePassive International Equity ETF 0.01

VALMXVL B1 0.00

Dimensional All Country LgCap Core 0.00

Takeda Pharmaceutical Company Limited Market Status

Strong Buy: 3

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Takeda Pharmaceutical Company Limited Fundamentals

Market Cap 56328.41 M

PB Ratio 1.1896

PE Ratio 81.0455

Enterprise Value 82611.09 M

Total Assets 14248344.00 M

Volume 2631311

Takeda Pharmaceutical Company Limited Company Financials

Annual Revenue FY25:4581551000000 4581551.0M, FY24:4263762000000 4263762.0M, FY23:4027478000000 4027478.0M, FY22:3569006000000 3569006.0M, FY21:3197812000000 3197812.0M

Annual Profit FY25:3001334000000 3001334.0M, FY24:2832257000000 2832257.0M, FY23:2783406000000 2783406.0M, FY22:2462160000000 2462160.0M, FY21:2203504000000 2203504.0M

Annual Net worth FY25:107928000000 107928.0M, FY24:144067000000 144067.0M, FY23:317017000000 317017.0M, FY22:230059000000 230059.0M, FY21:376005000000 376005.0M

Quarterly Revenue Q4/2025:1213211320000 1213211.3M, Q3/2025:1112796000000 1112796.0M, Q2/2025:1106685000000 1106685.0M, Q1/2025:1053400000000 1053400.0M, Q4/2024:1144124000000 1144124.0M

Quarterly Profit Q4/2025:660345606000 660345.6M, Q3/2025:732735000000 732735.0M, Q2/2025:722010000000 722010.0M, Q1/2025:671300000000 671300.0M, Q4/2024:727250000000 727250.0M

Quarterly Net worth Q4/2025:105509960000 105510.0M, Q3/2025:-11802000000 -11802.0M, Q2/2025:124243000000 124243.0M, Q1/2025:-103200000000 -103200.0M, Q4/2024:23789000000 23789.0M

About Takeda Pharmaceutical Company Limited & investment objective

Company Information Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Organisation Drug Manufacturers - Specialty & Generic

Employees 47455

Industry Drug Manufacturers - Specialty & Generic

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Takeda Pharmaceutical Company Limited FAQs

What is the share price of Takeda Pharmaceutical Company Limited today?

The current share price of Takeda Pharmaceutical Company Limited is $17.83.

Can I buy Takeda Pharmaceutical Company Limited shares in India?

Yes, Indian investors can buy Takeda Pharmaceutical Company Limited shares by opening an international trading and demat account with Motilal Oswal.

How to buy Takeda Pharmaceutical Company Limited shares in India?

You can easily invest in Takeda Pharmaceutical Company Limited shares from India by:

Can I buy fractional shares of Takeda Pharmaceutical Company Limited?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited has a market cap of $56328.41 M.

In which sector does Takeda Pharmaceutical Company Limited belong?

Takeda Pharmaceutical Company Limited operates in the Drug Manufacturers - Specialty & Generic sector.

What documents are required to invest in Takeda Pharmaceutical Company Limited stocks?

To invest, you typically need:

What is the PE and PB ratio of Takeda Pharmaceutical Company Limited?

The PE ratio of Takeda Pharmaceutical Company Limited is 81.05 and the PB ratio is 1.19.